Global Head & Neck Cancer Drugs Market (2022 to 2027) - Featuring AbbVie, Amgen and Gilead Sciences Among Others
August 24, 2022 05:08 ET
|
Research and Markets
Dublin, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The "Global Head & Neck Cancer Drugs Market (2022-2027) by Drug Class, Product, End User, Geography, Competitive Analysis and the Impact of Covid-19...
Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model
July 07, 2022 01:30 ET
|
Spexis AG
ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated...
Global Head & Neck Cancer Drugs Market Research Report (2021 to 2026) - by Drug Class, Product, End-user and Region
January 05, 2022 06:33 ET
|
Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Head & Neck Cancer Drugs Market Research Report by Drug Class, Product, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of...
Investigation Report on China's CNY1.112 Billion Docetaxel Market 2021-2025
December 31, 2021 05:43 ET
|
Research and Markets
Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Docetaxel Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. According to the market...
LIDDS tillkännager positiva topline resultat från den dos-eskalerande fas I studien av NanoZolid®-formulerad docetaxel
December 29, 2021 04:00 ET
|
LIDDS AB
UPPSALA, SVERIGE – LIDDS AB (publ) tillkännagav i dag att den systemiska exponeringen av docetaxel efter behandling av solida tumörer med NanoZolid®-formulerad docetaxel är låg och att studien visar...
LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
December 29, 2021 04:00 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study demonstrated activity in both...
Global Prostate Cancer Clinical Landscape Market Report 2021: Treatments, Epidemiology, Marketed Drugs, Pipeline Drugs, Regulatory Events, Clinical Trials, Drug Assessment, Future Trends
July 14, 2021 05:03 ET
|
Research and Markets
Dublin, July 14, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Prostate Cancer" report has been added to ResearchAndMarkets.com's offering. The publisher estimates that in 2018, there were 1.3...
Global Castrate Resistant Prostate Cancer Pipeline Insight Report 2020 Featuring Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma & ESSA Pharma
January 11, 2021 05:03 ET
|
Research and Markets
Dublin, Jan. 11, 2021 (GLOBE NEWSWIRE) -- The "Castrate Resistant Prostate Cancer - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Castrate...
Worldwide Prostate Cancer Industry to 2024 - Insights & Forecast with Potential Impact of COVID-19
December 23, 2020 07:18 ET
|
Research and Markets
Dublin, Dec. 23, 2020 (GLOBE NEWSWIRE) -- The "Global Prostate Cancer Market (by Cancer Type, Drug, Therapy & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)"...
Plus Therapeutics Appoints Dr. An van Es-Johansson to Board of Directors
January 02, 2020 16:15 ET
|
Plus Therapeutics, Inc.
AUSTIN, Texas, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that Dr. An van Es-Johansson has joined the Company’s Board of Directors to...